Amorphous Nilotinib Solid Dispersion for Food-Independent Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral formulations of nilotinib, such as TASIGNA, require patients to take the drug on an empty stomach and avoid food for a significant period, which is burdensome and can lead to poor adherence due to side effects exacerbated by food interactions.
Innovation Solution
Development of an amorphous solid dispersion (ASD) of nilotinib with polymers like HPMC-AS, which allows for administration without regard to food consumption, providing a stable and effective pharmacokinetic profile similar to conventional formulations at lower doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nilotinib is administered as conventional immediate-release formulation, then the drug can be effectively delivered, but patients must avoid food for significant periods which reduces adherence
Solution Approach 1:
The patent transforms nilotinib from a crystalline solid to an amorphous solid dispersion, fundamentally changing the physical state and dissolution characteristics of the drug. This parameter change enables the drug to dissolve rapidly in both fasted and fed states, eliminating the need for food restrictions while maintaining therapeutic efficacy and improving patient adherence
2Reliability
If nilotinib is taken with food, then patient adherence improves, but AUC and Cmax increase significantly causing side effects
Solution Approach 1:
The amorphous solid dispersion formulation creates a dynamic dissolution system that adapts to different gastrointestinal conditions. The formulation maintains consistent drug release kinetics whether the patient is fasted or fed, preventing the harmful spikes in AUC and Cmax that occur with conventional formulations taken with food, while still allowing flexible dosing
3Reliability
If nilotinib solubility is increased to improve bioavailability, then absorption improves, but formulation complexity increases
Solution Approach 1:
The patent creates an amorphous solid dispersion by combining nilotinib with a polymer matrix (such as HPMC-AS), forming a composite material system. This composite approach enhances solubility and bioavailability through the polymer's solubilizing effect while maintaining a relatively simple capsule or tablet formulation structure that is easy to manufacture and administer
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ASD formulation of nilotinib offers improved bioavailability and reduced inter-subject and intra-subject variability, enabling safer and more effective treatment with reduced side effects and increased patient adherence.
Implementation Method 1
amorphous solid dispersion (ASD) of nilotinib
Data Source
AI summary
Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor nilotinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer. In some embodiments, the pharmaceutical compositions can be administered without regard to food consumption. In other embodiments, the pharmaceutical compositions can be administered at a significantly lower dose as compared to a commercially available immediate-release nilotinib formulation, while providing a comparable therapeutic effect.